Manages spasticity. ANDA 213798, held by Rubicon Research. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 213798 (Tizanidine Hydrochloride), held by Rubicon Research, was first approved by FDA on May 27, 2020, with 0 approved supplements and 0 published complete response letters.
Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 27, 2020 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 8MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters